The American Diabetes Association (Arlington, VA, USA) and the American Association of Clinical Endocrinology (Jacksonville, FL, USA) recommend GLP-1 RAs as first-line drugs along with metformin for patients with type 2 diabetes with an established or high risk of atherosclerotic cardiovascular disease, stroke, transient ischemic attacks, or chronic kidney disease. The gene discussed is GLP1R; the disease is diabetes mellitus.